Laboratory of Medical and Molecular Oncology (LMMO) comprises a clinical Department of Medical Oncology of the Oncologisch Centrum UZ Brussel and a Laboratory of Molecular Oncology in the Faculty of Medicine. The aim of the group is to help advance targeted therapies for cancer in genomically defined patients (personalized medicine).
- Clinical studies
- to assess the tolerability and efficacy of novel systemic treatments of cancer (phase I, II, III); sponsored and academic studies.
- that aim at increasing the quality of cancer care: studies in supportive care, toxicity control, end of life and geriatric oncology
- in various cancer types that specifically aim at correlating biomarkers with the clinical efficacy of novel cancer treatments. A major focus is on genomic biomarker research. Investigator initiated translational studies in following tumor types: lung cancer, brain tumors, melanoma, sarcoma and esophageal cancer.
- Cancer vaccination studies in collaboration with the LMCT
- Circulating tumor and endothelial cells, as an explorative biomarker in some of these translational studies and also as a source for tumor DNA, which might be useful, especially when adequate tumor biopsies are not available.
- Preclinical assessment of anticancer agents with a focus on the HER pathway in BA/F3 cells.
- Preclinical siRNA development to specifically inhibit mutant receptors that are resistant to tyrosine kinase inhibitors and investigation to apply this in vivo.
- Genetic cancer with an emphasis on breast/ovarian cancer in relationship to the Familial Cancer Clinic of the Oncology Centre
a. Clinical research in methodology of cancer genetic counseling
b. Research in breast cancer predisposition genes
c. Participation in clinical development of specific targeted agents in genetic cancer,
including synthetic lethality with PARP inhibitors.